Patients with glioblastoma have poor outcomes due to local relapse despite surgery and high-dose radiotherapy. Resistance to radiotherapy is thought to be due to efficiency of DNA repair cells, such as RAD51, are able to survive DNA damage from radiotherapy and repopulate the tumour post treatment.
Using Xstrahl’s SARRP, Harry King et al. used clinical patient derived glioblastoma stem cells to confirm RAD51 is highly expressed in the condition. Furthering this, the study “RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells” then went on to treat these cells with RI-1 and B02 inhibitors, demonstrating that treatment with these agents, combined with radiotherapy, are able to prevent RAD51 focus formation, reduce DNA repair and result in significant radiosensitization.
The study therefore indicates that the treatment of glioblastomas focusing on specific targeted RAD51 cells can dramatically improve the likelihood of relapsed tumours.
To find out more about the science being conducted with Xstrahl Life Science systems you can investigate Xstrahl’s SARRP for the latest developments. Additionally, you can find out how Xstrahl Medical systems are being used to treat a series of conditions.
This Xstrahl In Action was adapted from a article found on a National Library of Medicine website.
